Devices, digital health, and the technology changing how care is delivered.
HTI-5 proposed regulations seek to modernize health IT and interoperability, but ACP warns the degree of change and accelerated implementation period are too aggressive.
Toolkit Clinical decision support (CDS) alerts can signal the existence of conditions that degrade care quality. This toolkit provides primary care and other ambulatory care environments steps to amend information systems to adopt a community-acquired pneumonia (CAP) alert to improve workflows that affect the diagnosis and management of CAP. Available at Agency for Healthcare Research and Quality . Share Facebook <a tabindex="0" class="dropdown-item" target="_blank" rel="nofollow" href="https://twitter.com/share?text=Community-Acquired Pneumonia Clinical Decision Support Implementation…
Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further development of its foundational platform.
A Dexcom continuous glucose monitor helped adults with type 2 diabetes not using insulin improve blood sugar control in a randomized trial, adding new fuel to the industry’s push to bring CGMs into broader primary care use.
ResMed has closed its $340 million acquisition of Noctrix Health, picking up a wearable neuromodulation device that pushes the sleep tech giant beyond its core sleep apnea and respiratory care businesses.
Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of the public market. Treeline has announced plans to merge with omics outfit Standard BioTools and secure a listing on the Nasdaq.
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.
Incyte has struck a deal to buy a Star Therapeutics subsidiary for $1.25 billion upfront. The takeover, the biggest bet of Bill Meury’s time as CEO, covers a late-phase bleeding disorder drug candidate that could support Incyte’s ambition to grow through the loss of patent protection for Jakafi in 2028.
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?
RevHealth CEO Ben Beckley shares how integrated teams are helping biopharma organizations align strategy, break down silos and drive stronger commercial impact.
SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development speed.
AI is accelerating discovery, but only when paired with expert insight and trusted data. Hear how leaders are rethinking decision-making in biopharma.
With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
Unlearn founder and head of AI, Aaron Smith, on how digital twins are moving from trial simulation into the full chain of decisions sponsors make — and what regulators need to see along the way.
Strategy matters—but execution separates leaders. Hear how top biopharma teams translate strategy into results.
PhaseV CEO Raviv Pryluk explains how AI is reshaping trial design and execution.
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog, petrelintide.
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.